WHO back again with results from "study" claiming no medication works against COVID 1/2
link to pre-print of study:
https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.full.pdf
NOTE: the study has not been peer-reviewed yet
Study:
Repurposed antiviral drugs for COVID-19 – interim WHO SOLIDARITY trial results
ABSTRACT
BACKGROUND
WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs.
METHODS
Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a (mainly subcutaneous; initially with Lopinavir, later not). COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control (up to 5 options: 4 active and local standard-of-care). The intent-to-treat primary analyses are of in-hospital mortality in the 4 pairwise comparisons of each study drug vs its controls (concurrently allocated the same management without that drug, despite availability). Kaplan-Meier 28-day risks are unstratified; log-rank death rate ratios (RRs) are stratified for age and ventilation at entry.
RESULTS
In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug. Compliance was 94-96% midway through treatment, with 2-6% crossover. 1253 deaths were reported (at median day 8, IQR 4-14). Kaplan-Meier 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise). Death rate ratios (with 95% CIs and numbers dead/randomized, each drug vs its control) were: Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control), Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372) and Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050). No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.
CONCLUSIONS
These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials. (Funding: WHO. Registration: ISRCTN83971151, NCT04315948)
Anon theory:
Did POTUS' admin know in advance they were going to time the release of a non peer-reviewed version of this "study" around the schedule of the US presidential election, and to counter the "neither HCQ nor Remdesivir nor Interferon nor Lopinavir/Ritonavir works" narrative (AKA the "COVID=DEATH SENTENCE" narrative), POTUS took BOTH Regeneron AND Remdesivir:
-
Remdesivir to sidetrack the cabal -"muah ah ah, that fool doesn't know we're going to tank that crap med soon, we'll play along for now. But next, we'll tell everyone he was never sick in the first place"
-
The WH was vague about the use of Regeneron, let it sound like Remdesivir was the main medication. The cabal smelt a rat though, and tried to attack the monoclonal antibody therapy
-
POTUS comes back, only names Regeneron in his comeback video, and says he took other things, but he felt it was the Regeneron that did it
-
MSM tried to downplay Regeneron, drawing attention to the fact he also took Remdesivir
-
But now, thanks to that WHO "study", the public knows there is a medication that works, and that it cannot be Remdesivir, since the WHO just tanked it
-
"POTUS was not sick" controversy avoided
"There is no cure/COVID=DOOM" controversy avoided
HCQ controversy [anons and awaken citizens still know it works]
If theory correct -nicely played 4D-game theory ladies and good sirs at the WH!